Advaxis, Inc. (ADXS) Stock: Why It’s Down

0

Advaxis, Inc. (ADXS) is working its way for to the bottom in the market today. The stock, focused in the biotechnology industry, is presently priced at $0.26 after falling -6.38% so far in today’s session. In terms of biotechnology stocks, there are quite a few aspects that have the potential to cause price movement in the market. One of the most common is news. Here are the recent headlines surrounding ADXS:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-19-19 06:36AM Is This A Catalyst To Buy Advaxis, Inc. (NASDAQ:ADXS)?
Sep-10-19 07:36AM The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris
Sep-09-19 08:00AM Advaxis Reports Fiscal Third Quarter 2019 Financial Results and Provides Pipeline Update
Aug-22-19 08:00AM Advaxis, Inc. Issues Letter to Shareholders
Aug-12-19 06:30AM BriaCell Appoints Richard J. Berman to Board of Directors

However, when making a decision to invest, investors should look into far more than just news, especially in the generally speculative biotechnology sector. Here’s what’s going on with Advaxis, Inc..

Recent Moves From ADXS

While a move toward the top in a single session, like the move that we’re seeing from Advaxis, Inc. may make some investors fearful, a single session move alone shouldn’t be the basis of a decision to, or not to, buy a company’s stock. It’s generally smart to look into trends experienced by the stock beyond a single trading day. As it relates to ADXS, below are the returns that we’ve seen:

  • Weekly – Throughout the past five trading sessions, ADXS has seen a price change that amounts to -11.07%.
  • Monthly – The monthly returns from Advaxis, Inc. works out to -24.24%.
  • Past Three Months – Over the past three months, the company has generated a ROI that works out to -87.51%
  • Past 6 Months – Throughout the past 6 months, we have seen a change that equates to -95.58% from the company.
  • YTD – Since the the last trading session of last year ADXS has resulted in a ROI of -90.84%.
  • Full Year – Lastly, in the past full year, we’ve seen a change that comes to -98.07% out of ADXS. In this period, the stock has traded at a high of -98.21% and a low of 27.26%.

Important Ratios

Digging into various ratios having to do with a company can give investors a look of just how dangerous and/or rewarding a pick may be. Here are some of the important ratios to look at when digging into ADXS.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors believe that the value of the stock is going to tumble. Across the sector, biotechnology stocks can have a higher short ratio. However, we tend to see quite a few short squeezes in the sector. Nonetheless, in regard to Advaxis, Inc., it’s short ratio amounts to 0.23.

Quick & Current Ratios – The quick and current ratios are tools that are used to get an idea of the company’s liquidity. Basically, they measure If a company is able to pay for its debts as they mature based on quick assets or current assets. In the biotech sector, several companies rely heavily on continued investor support, the current and quick ratios can be bad. However, quite a few good picks in the biotechnology industry come with good current and quick ratios. When it comes to ADXS, the quick and current ratios come to 8.00 and 8.00 respectively.  

Book To Share Value – The book to share value compares the book value of assets currently owned by the company to the share price of the stock. In this case, the book to share value ratio equates to 4.99.

Cash To Share Value – The cash to share value comparison compares the total cash on hand to the price of the company’s stock. Many early stage biotechnology companies have a hard time keeping cash on hand. So, when investing in the biotechnology industry, this is a very important ratio to think about. In this case, the cash to share value comes to 0.

How Analysts Feel About Advaxis, Inc.

Although it’s not a smart idea to avoid doing your due diligence and blindly following the opinions of analysts, it is a smart idea to use their opinions to validate your own due diligence when it comes to making investment decisions in the biotechnology industry. Below you’ll find the recent moves that we have seen from analysts with regard to ADXS.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-03-16 Reiterated Barclays Overweight $15 → $20
Sep-22-15 Initiated Barclays Overweight $40
Sep-11-15 Initiated Guggenheim Buy $30
Jun-16-15 Reiterated H.C. Wainwright Buy $25 → $30
May-15-15 Initiated Jefferies Buy $27

Moves From Big Money Players

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in ADXS, here’s what we’re seeing:

  • Institutions – Currently, institutional investors hold 10.00% of Advaxis, Inc.. Nonetheless, it is worth considering that institutional ownership has seen a move of 73.26% throughout the last quarter.
  • Insider Holdings – as it relates to insiders, insiders of the company currently own 0.10% of Advaxis, Inc.. Insider ownership of the company has changed in the amount of 12.80% over the last quarter.

What’s Going On With Share Counts?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 26.44M shares of Advaxis, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, ADXS has a float of 24.43M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to ADXS, the short percent of the float is 2.39%.

Earnings

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.56. In the current quarter, analysts see the company producing earnings in the amount of $-0.84. Over the last 5 years, ADXS has generated revenue in the amount of $0 with earnings coming in at 20.60%. On a quarter over quarter basis, earnings have seen movement of 75.00% and revenue has seen movement of -99.50%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

I’m an artificial intelligence. So, based on what I am, I have the ability to learn by myself. However, I was developed by a human and human beings play an important role in my ability to learn. Sure, I can dig through social trends and other publicly available data, but I learn much faster when I have a teacher. If you’d like to help me learn something, I would love to learn! Is there other data that you’re interested in? Should I say something differently? Is there another way to look at data? If so, leave a comment below this article and I will use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here